Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension

Circulation

Volumn 128, Issue 5, 2013, Pages 512-523

  Hadri, Lahouaria ^a   Kratlian, Razmig G ^a   Benard, Ludovic ^a   Maron, Bradley A ^b   Dorfmüller, Peter ^c,d   Ladage, Dennis ^a   Guignabert, Christophe ^c   Ishikawa, Kiyotake ^a   Aguero, Jaume ^a   Ibanez, Borja ^e   Turnbull, Irene C ^a   Kohlbrenner, Erik ^a   Liang, Lifan ^a   Zsebo, Krisztina ^f   Humbert, Marc ^c,d   Hulot, Jean Sébastien ^a   Kawase, Yoshiaki ^a   Hajjar, Roger J ^a   Leopold, Jane A ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HÔPITAL ANTOINE BÉCLÈRE   (France)

^d CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^e CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^f Celladon Corporation   (United States)

Author keywords

calcium; gene therapy; heart failure; muscle, smooth; pulmonary hypertension; ventricular remodeling

Indexed keywords

BETA GALACTOSIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MONOCROTALINE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; SODIUM CHLORIDE; STAT3 PROTEIN; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD VESSEL INJURY; CALCIUM HOMEOSTASIS; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME ACTIVATION; FIBROSIS; GENE OVEREXPRESSION; GENE TRANSFER; HEART HEMODYNAMICS; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SEROTYPE; SMOOTH MUSCLE FIBER; SYSTEMIC CIRCULATION; VASCULAR SMOOTH MUSCLE; VIRAL GENE DELIVERY SYSTEM;

CALCIUM; GENE THERAPY; HEART FAILURE; MUSCLE, SMOOTH; PULMONARY HYPERTENSION; VENTRICULAR REMODELING;

ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE TRANSFER TECHNIQUES; HEART VENTRICLES; HEK293 CELLS; HUMANS; HYPERTENSION, PULMONARY; MALE; MONOCROTALINE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; TREATMENT OUTCOME;

EID: 84881105043     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.001585     Document Type: Article

References (42)

1. McLaughlin VV. Looking to the future: A new decade of pulmonary arterial hypertension therapy. Eur Respir Rev. 2011;20:262-269.
2. Davies RJ, Morrell NW. Molecular mechanisms of pulmonary arterial hypertension: Role of mutations in the bone morphogenetic protein type II receptor. Chest. 2008;134:1271-1277.
3. Voelkel NF, Cool C. Pathology of pulmonary hypertension. Cardiol Clin. 2004;22:343-51, v.
4. Rubin LJ, Simonneau G, Badesch D, Galiè N, Humbert M, Keogh A, Massaro J, Matucci Cerinic M, Sitbon O, Kymes S. The study of risk in pulmonary arterial hypertension. Eur Respir Rev. 2012;21:234-238.
5. Lipskaia L, del Monte F, Capiod T, Yacoubi S, Hadri L, Hours M, Hajjar RJ, Lompré AM. Sarco/endoplasmic reticulum Ca2+-ATPase gene transfer reduces vascular smooth muscle cell proliferation and neointima formation in the rat. Circ Res. 2005;97:488-495.
6. Lipskaia L, Chemaly ER, Hadri L, Lompre AM, Hajjar RJ. Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure. Expert Opin Biol Ther. 2010;10:29-41.
7. Bobe R, Hadri L, Lopez JJ, Sassi Y, Atassi F, Karakikes I, Liang L, Limon I, Lompré AM, Hatem SN, Hajjar RJ, Lipskaia L. SERCA2a controls the mode of agonist-induced intracellular Ca2+ signal, transcription factor NFAT and proliferation in human vascular smooth muscle cells. J Mol Cell Cardiol. 2011;50:621-633.
8. Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN, Michelakis ED. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A. 2007;104:11418-11423.
9. Lagunas L, Clipstone NA. Deregulated NFATc1 activity transforms murine fibroblasts via an autocrine growth factor-mediated Stat3-dependent pathway. J Cell Biochem. 2009;108:237-248.
10. Paulin R, Courboulin A, Meloche J, Mainguy V, Dumas de la Roque E, Saksouk N, Côté J, Provencher S, Sussman MA, Bonnet S. Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation. 2011;123:1205-1215.
11. Kawase Y, Hajjar RJ. The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: A potent target for cardiovascular diseases. Nat Clin Pract Cardiovasc Med. 2008;5:554-565.
12. del MonteF, Harding SE, Schmidt U, Matsui T, Kang ZB, Dec GW, Gwathmey JK, Rosenzweig A, Hajjar RJ. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation. 1999;100:2308-2311.
13. Aramburu J, Garcia-Cózar F, Raghavan A, Okamura H, Rao A, Hogan PG. Selective inhibition of NFAT activation by a peptide spanning the calcineurin targeting site of NFAT. Mol Cell. 1998;1:627-637.
14. Aramburu J, Yaffe MB, López-Rodríguez C, Cantley LC, Hogan PG, Rao A. Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science. 1999;285:2129-2133.
15. Karakikes I, Hadri L, Rapti K, Ladage D, Ishikawa K, Tilemann L, Yi GH, Morel C, Gwathmey JK, Zsebo K, Weber T, Kawase Y, Hajjar RJ. Concomitant intravenous nitroglycerin with intracoronary delivery of AAV1.SERCA2a enhances gene transfer in porcine hearts. Mol Ther. 2012;20:565-571.
16. Maron BA, Zhang YY, White K, Chan SY, Handy DE, Mahoney CE, Loscalzo J, Leopold JA. Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension. Circulation. 2012;126:963-974.
17. Hessel MH, Steendijk P, den Adel B, Schutte CI, van der Laarse A. Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. Am J Physiol Heart Circ Physiol. 2006;291:H2424-H2430.
18. Schultze AE, Roth RA. Chronic pulmonary hypertension-the monocrotaline model and involvement of the hemostatic system. J Toxicol Environ Health B Crit Rev. 1998;1:271-346.
19. Werchan PM, Summer WR, Gerdes AM, McDonough KH. Right ventricular performance after monocrotaline-induced pulmonary hypertension. Am J Physiol. 1989;256(5 Pt 2):H1328-H1336.
20. Gao Y, Raj JU. Regulation of the pulmonary circulation in the fetus and newborn. Physiol Rev. 2010;90:1291-1335.
21. Fishman AP, Fishman MC, Freeman BA, Gimbrone MA, Rabinovitch M, Robinson D, Gail DB. Mechanisms of proliferative and obliterative vascular diseases. Insights from the pulmonary and systemic circulations. NHLBI Workshop summary. Am J Respir Crit Care Med. 1998;158:670-674.
22. Clark JH, Kinnear NP, Kalujnaia S, Cramb G, Fleischer S, Jeyakumar LH, Wuytack F, Evans AM. Identification of functionally segregated sarcoplasmic reticulum calcium stores in pulmonary arterial smooth muscle. J Biol Chem. 2010;285:13542-13549.
23. Mahn K, Hirst SJ, Ying S, Holt MR, Lavender P, Ojo OO, Siew L, Simcock DE, McVicker CG, Kanabar V, Snetkov VA, O'Connor BJ, Karner C, Cousins DJ, Macedo P, Chung KF, Corrigan CJ, Ward JP, Lee TH. Diminished sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) expression contributes to airway remodelling in bronchial asthma. Proc Natl Acad Sci U S A. 2009;106:10775-10780.
24. Sahara M, Sata M, Morita T, Hirata Y, Nagai R. Nicorandil attenuates monocrotaline-induced vascular endothelial damage and pulmonary arterial hypertension. PLoS One. 2012;7:e33367.
25. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333:214-221.
26. Hadri L, Bobe R, Kawase Y, Ladage D, Ishikawa K, Atassi F, Lebeche D, Kranias EG, Leopold JA, Lompré AM, Lipskaia L, Hajjar RJ. SERCA2a gene transfer enhances eNOS expression and activity in endothelial cells. Mol Ther. 2010;18:1284-1292.
27. Niemeyer GP, Herzog RW, Mount J, Arruda VR, Tillson DM, Hathcock J, van Ginkel FW, High KA, Lothrop CD Jr. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood. 2009;113:797-806.
28. Hajjar RJ, Zsebo K, Deckelbaum L, Thompson C, Rudy J, Yaroshinsky A, Ly H, Kawase Y, Wagner K, Borow K, Jaski B, London B, Greenberg B, Pauly DF, Patten R, Starling R, Mancini D, Jessup M. Design of a phase - trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail. 2008;14:355-367.
29. Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B, Borow K, Dittrich H, Zsebo KM, Hajjar RJ; Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease (CUPID) Trial Investigators. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-inhuman phase - clinical trial. J Card Fail. 2009;15:171-181.
30. Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, Yaroshinsky A, Zsebo KM, Dittrich H, Hajjar RJ; Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) Investigators. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011;124:304-313.
31. Chen S, Kapturczak M, Loiler SA, Zolotukhin S, Glushakova OY, Madsen KM, Samulski RJ, Hauswirth WW, Campbell-Thompson M, Berns KI, Flotte TR, Atkinson MA, Tisher CC, Agarwal A. Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors. Hum Gene Ther. 2005;16:235-247.
32. Song Y, Jones JE, Beppu H, Keaney JF Jr, Loscalzo J, Zhang YY. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation. 2005;112:553-562.
33. Moss RB, Milla C, Colombo J, Accurso F, Zeitlin PL, Clancy JP, Spencer LT, Pilewski J, Waltz DA, Dorkin HL, Ferkol T, Pian M, Ramsey B, Carter BJ, Martin DB, Heald AE. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: A randomized placebo-controlled phase 2B trial. Hum Gene Ther. 2007;18:726-732.
34. Angelini DJ, Su Q, Kolosova IA, Fan C, Skinner JT, Yamaji-Kegan K, Collector M, Sharkis SJ, Johns RA. Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELM alpha) recruits bone marrow-derived cells to the murine pulmonary vasculature. PLoS One. 2010;5:e11251.
35. Angelini DJ, Su Q, Yamaji-Kegan K, Fan C, Skinner JT, Champion HC, Crow MT, Johns RA. Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELMalpha) induces the vascular and hemodynamic changes of pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2009;296:L582-L593.
36. Ito T, Okada T, Mimuro J, Miyashita H, Uchibori R, Urabe M, Mizukami H, Kume A, Takahashi M, Ikeda U, Sakata Y, Shimada K, Ozawa K. Adenoassociated virus-mediated prostacyclin synthase expression prevents pulmonary arterial hypertension in rats. Hypertension. 2007;50:531-536.
37. Ito T, Okada T, Miyashita H, Nomoto T, Nonaka-Sarukawa M, Uchibori R, Maeda Y, Urabe M, Mizukami H, Kume A, Takahashi M, Ikeda U, Shimada K, Ozawa K. Interleukin-10 expression mediated by an adenoassociated virus vector prevents monocrotaline-induced pulmonary arterial hypertension in rats. Circ Res. 2007;101:734-741.
38. Kido M, Du L, Sullivan CC, Deutsch R, Jamieson SW, Thistlethwaite PA. Gene transfer of a TIE2 receptor antagonist prevents pulmonary hypertension in rodents. J Thorac Cardiovasc Surg. 2005;129:268-276.
39. Kataoka M, Kawakami T, Tamura Y, Yoshino H, Satoh T, Tanabe T, Fukuda K. Gene transfer therapy by either type 1 or type 2 adeno-associated virus expressing human prostaglandin I2 synthase gene is effective for treatment of pulmonary arterial hypertension. J Cardiovasc Pharmacol Ther. 2013;18:54-59.
40. Kawakami T, Kanazawa H, Satoh T, Ieda M, Ieda Y, Kimura K, Mochizuki H, Shimada T, Yokoyama C, Ogawa S, Tanabe T, Fukuda K. AAV-PGIS gene transfer improves hypoxia-induced pulmonary hypertension in mice. Biochem Biophys Res Commun. 2007;363:656-661.
41. Kawase Y, Ly HQ, Prunier F, Lebeche D, Shi Y, Jin H, Hadri L, Yoneyama R, Hoshino K, Takewa Y, Sakata S, Peluso R, Zsebo K, Gwathmey JK, Tardif JC, Tanguay JF, Hajjar RJ. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol. 2008;51:1112-1119.
42. Hadri L, Hajjar RJ. Calcium cycling proteins and their association with heart failure. Clin Pharmacol Ther. 2011;90:620-624.